Updates in neuroendocrine neoplasms: From mechanisms to the clinic - 01/04/23

Doi : 10.1016/j.ando.2022.12.424

Sarah Fodil-Cherif ^a,^⁎ , Rachel Desailloud ^b, Thierry Brue ^c,^d
^a Service d’endocrinologie, diabète, CHU de Lapeyronie, 371, avenue du Doyen Gaston Giraud, 34090 Montpellier, France
^b Service d’endocrinologie, diabétologie, nutrition, Hôpital Nord, Centre Hospitalo-Universitaire-Université Picardie Jules Vernes d’Amiens, 2, Place Victor Pauchet, 80080 Amiens, France
^c Assistance Publique-Hôpitaux de Marseille (AP-HM), service d’endocrinologie, hôpital de la Conception, Centre de Référence des Maladies Rares de l’hypophyse HYPO, 147, Boulevard Baille, 13005 Marseille, France
^d 2 Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale (INSERM), U1251, Marseille Medical Genetics (MMG), Institut Marseille Maladies Rares (MarMaRa), Marseille, France

^⁎Corresponding author.

connettersi o creare un account

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Scientific advances constantly improve our understanding of the mechanisms underlying tumorigenesis, allowing us now to analyze cancer in a more precise manner and to identify at an earlier stage the tumors that have greater risk of aggressive behavior. Understanding neuroendocrine neoplasms at molecular level has enabled increasingly targeted treatments, with safety and efficacy validated in large randomized trials. Moreover, the first studies of targeted therapies after molecular profiling of neuroendocrine neoplasms have shown encouraging results, allowing us to foresee ever more personalized medical treatments in the future. This literature review aims to summarize recent advances in the study of neuroendocrine neoplasms and to show how identification of new mechanisms underlying tumorigenesis can be of benefit in clinical practice.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Neuroendocrine neoplasm, Neuroendocrine carcinoma, Pituitary, Pheochromocytoma, Paraganglioma, Personalized medicine